Three Seasons Wealth LLC Sells 2,842 Shares of IDEXX Laboratories, Inc. $IDXX

Three Seasons Wealth LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 55.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,284 shares of the company’s stock after selling 2,842 shares during the quarter. Three Seasons Wealth LLC’s holdings in IDEXX Laboratories were worth $1,545,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Blalock Williams LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $590,000. New York State Common Retirement Fund raised its stake in shares of IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after buying an additional 3,820 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the period. Mediolanum International Funds Ltd boosted its position in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after acquiring an additional 4,909 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of IDEXX Laboratories by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after acquiring an additional 187,967 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at $11,511,734.37. The trade was a 8.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $561.89 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The firm has a market cap of $44.63 billion, a P/E ratio of 42.99, a P/E/G ratio of 3.38 and a beta of 1.66. The business’s fifty day moving average is $625.67 and its two-hundred day moving average is $660.90. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company posted $2.53 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IDXX. UBS Group lowered their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Piper Sandler dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $772.22.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.